IRIS
MIGLINO, MAURIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 13.093
AS - Asia 1.518
NA - Nord America 1.159
SA - Sud America 128
AF - Africa 23
OC - Oceania 5
Totale 15.926
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 12.816
US - Stati Uniti d'America 1.070
SG - Singapore 600
CN - Cina 387
VN - Vietnam 232
BD - Bangladesh 141
FR - Francia 104
BR - Brasile 83
HK - Hong Kong 48
FI - Finlandia 32
CA - Canada 29
DE - Germania 25
GB - Regno Unito 25
AR - Argentina 24
MX - Messico 21
JP - Giappone 20
IQ - Iraq 14
IN - India 13
CH - Svizzera 12
NL - Olanda 11
PH - Filippine 11
JM - Giamaica 9
ID - Indonesia 8
TR - Turchia 8
UA - Ucraina 8
CR - Costa Rica 6
ES - Italia 6
IE - Irlanda 6
VE - Venezuela 6
AU - Australia 5
RU - Federazione Russa 5
AL - Albania 4
DZ - Algeria 4
EC - Ecuador 4
GR - Grecia 4
HN - Honduras 4
PK - Pakistan 4
RO - Romania 4
TH - Thailandia 4
ZA - Sudafrica 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
CO - Colombia 3
GT - Guatemala 3
KR - Corea 3
NI - Nicaragua 3
PL - Polonia 3
PY - Paraguay 3
RS - Serbia 3
SI - Slovenia 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BE - Belgio 2
BY - Bielorussia 2
CL - Cile 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
IR - Iran 2
KE - Kenya 2
LT - Lituania 2
MA - Marocco 2
MG - Madagascar 2
PE - Perù 2
PR - Porto Rico 2
PT - Portogallo 2
SE - Svezia 2
SY - Repubblica araba siriana 2
TZ - Tanzania 2
UZ - Uzbekistan 2
AG - Antigua e Barbuda 1
AO - Angola 1
AT - Austria 1
BF - Burkina Faso 1
BH - Bahrain 1
BS - Bahamas 1
CG - Congo 1
CI - Costa d'Avorio 1
CU - Cuba 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EG - Egitto 1
GD - Grenada 1
HR - Croazia 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
MF - Saint Martin 1
MK - Macedonia 1
MT - Malta 1
NO - Norvegia 1
NP - Nepal 1
PS - Palestinian Territory 1
QA - Qatar 1
SA - Arabia Saudita 1
Totale 15.924
Salva come PNG Salva come JPEG
Città #
Genova 6.720
Genoa 3.832
Rapallo 1.216
Vado Ligure 828
San Jose 323
Singapore 281
Ashburn 113
Lauterbourg 91
Ho Chi Minh City 71
Beijing 69
New York 66
Hanoi 48
Hong Kong 46
Milan 37
Council Bluffs 34
Helsinki 32
Bordighera 31
Santa Clara 24
Frankfurt am Main 23
Los Angeles 23
Tokyo 17
Rome 15
Mexico City 14
Valenza 12
Zurich 11
Buffalo 10
Da Nang 10
Dallas 10
Chicago 9
Montreal 9
Naples 8
Phoenix 8
Tianjin 8
Toronto 8
Amsterdam 7
Boardman 7
Cardiff 7
Las Vegas 7
Orem 7
Paris 7
São Paulo 7
Atlanta 6
Biên Hòa 6
Dublin 6
Hải Dương 6
Ninh Bình 6
San José 6
Turin 6
Baghdad 5
Brooklyn 5
Denver 5
Dhaka 5
Haiphong 5
Kingston 5
Louisville 5
Miami 5
Newark 5
Sydney 5
Bắc Ninh 4
Can Tho 4
Charlotte 4
City of London 4
Istanbul 4
Jacksonville 4
Johannesburg 4
London 4
Perugia 4
Rovereto 4
Abu Dhabi 3
Baku 3
Baltimore 3
Bari 3
Buenos Aires 3
Chennai 3
Corrientes 3
Des Moines 3
Guangzhou 3
Ljubljana 3
Madrid 3
Manchester 3
Marseille 3
Mumbai 3
Philadelphia 3
Phủ Lý 3
Pinehurst 3
San Francisco 3
San Juan 3
San Pedro Sula 3
Shanghai 3
Stone Mountain 3
The Dalles 3
Washington 3
Addis Ababa 2
Alexandria 2
Algiers 2
Ankara 2
Antananarivo 2
Athens 2
Bandung 2
Basingstoke 2
Totale 14.326
Salva come PNG Salva come JPEG
Nome #
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 248
Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes 228
A novel Bim-BH3-derived Bcl-X(L) inhibitor: Biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activity 225
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia 224
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients 218
Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse 216
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis 214
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas 211
Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation 209
Doxorubicin effect on myocardial metabolism as a prerequisite for subsequent development of cardiac toxicity: A translational18F-FDG PET/CT observation 209
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients 207
A case of Cunninghamella bertholettiae rhino-cerebral infection in a leukaemic patient and review of recent published studies 205
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives 204
Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission. 202
Adult Advanced Chronic Lymphocytic Leukemia: Computational Analysis of Whole-Body CT Documents a Bone Structure Alteration 201
Feasibility and Efficacy of Post-Transplant Consolidation Immunotherapy with Nivolumab Supported By the Reinfusion of Unselected Autologous Lymphocytes in Patients Affected By Relapsed/Refractory Hodgkin Lymphoma 200
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia 197
Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes 196
Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. 190
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. 188
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 188
Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients. 185
Evaluating treatment response of chronic myeloid leukemia: emerging science and technology. 180
An increase in myocardial 18-fluorodeoxyglucose uptake is associated with left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with anthracycline 180
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 180
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. 177
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 176
Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients 175
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents 174
Amifostine promotes hemopoietic progenitor cell mobilization in patients with myelodysplastic syndrome. 174
Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma 173
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question". 173
First line therapy with Fludarabine combinations in 42 patients with either post-myelodysplastic syndrome or therapy related acute myeloid leukaemia. 171
Molecular analysis of clonality in plasma cell dyscrasias. 171
Dual NAMPT and BTK targeting leads to synergistic killing of Waldenström macroglobulinemia cells regardless of MYD88 and CXCR4 somatic mutation status 169
Combination of liposomal Daunorubicin, Fludarabine, and Cytarabine (FLAD) in patients with poor- risk acute leukemia. 168
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach 168
Chronic graft versus host disease as a weapon for treating chronic myelomonocytic leukemia 166
Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. 165
Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: A Possible Role for RANK/RANKL Pathway 162
Thalidomide in agnogenic and secondary myelofibrosis 161
Bound and unbound pyridine dinucleotides in normal and glucose-6-phosphate dehydrogenase-deficient erythrocytes. 161
Molecular analysis of the bcr rearrangement in a case of Ph'-negative blastic crisis of Ph'-positive chronic myelogenous leukemia. 160
Clonal B lymphocytes lack bcr rearrangement in Ph-positive chronic myelogenous leukaemia. 158
Amino acid depletion triggered by L-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death 158
First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease 157
Hepatosplenic T-cell lymphoma with aberrant expression of serum β-HCG: A case report 157
Early chemotherapy intensification with escalated beacopp in patients with advanced-stage hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two abvd cycles: Long-term results of the GITIL/FIL HD 0607 trial 155
Chronic lymphocytic leukemia cells impair osteoblastogenesis and promote osteoclastogenesis: role of TNFα, IL-6 and IL-11 cytokines 153
Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia 152
Epigenetic Regulation in Myelodysplastic Syndrome as A Consequence of A MicroRNA Dysregulation 152
Prompt detection of L-asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas 151
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 150
Polyclonal pattern of X-inactivation in multiple myeloma. 150
Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia 150
An unusual reaction to alpha interferon in a case of non Hodgkin's lymphoma. 149
Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity. 148
Fludarabine, high-dose cytarabine and idarubicin-based induction may overcome the negative prognostic impact of flt3-itd in npm1 mutated aml, irrespectively of flt3-itd allelic Burden 148
Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia. 147
Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis. 146
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: A feasible and effective salvage treatment for lymphoid malignancies 146
Complex chromosome rearrangements may locate the bcr/abl fusion gene sites other than 22q11 145
Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia 143
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis 143
Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients. 142
Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. 141
Effects of TNF-α inhibitors upon the mechanisms of action of VEGF. 141
WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. 140
Impact of hematological malignancies in patients undergoing cardiac surgery 139
Masked Philadelphia chromosome due to atypical BCR/ABL localization on the 9q34 band and duplication of the der(9) in a case of chronic myelogenous leukemia 138
Ras activation in myelodysplastic syndromes: clinical and molecular study of the chronic phase of the disease. 137
Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression. 136
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment 134
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia. 133
Clonal analysis of hematologic malignancies using Mediterranean G6PD mosaicism. 131
A new glucose-6-phosphate dehydrogenase variant with congenital nonspherocytic hemolytic anemia (G6PD Genova). Biochemical characterization and mosaicism expression in the heterozygote. 131
SIRT6 inhibition as a novel approach for treating Acute Myeloid Leukemia 129
Molecular analysis of patients with relapsed or refractory intermediate-high grade non-Hodgkin’s lymphoma with bone marrow infiltration undergoing peripheral blood progenitor cell transplantation 127
FRONT-LINE TREATMENT OF PHILADELPHIA POSITIVE CHRONIC MYELOID LEUKEMIA WITH IMATINIB AND INTERFERON-ALPHA: 5-YEAR OUTCOME. 120
High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. 119
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis 118
Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes. 118
A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML 117
Cutaneous manifestations of hematologic malignancies the experience of an Italian dermatology department 114
Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing and allogeneic bone marrow transplant 110
Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia. 110
Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ chronic myeloid leukemia patients treated with Imatinib mesylate. 109
Mobilization/transplantation of peripheral blood progenitor cells for aggressive non-Hodgkin's lymphoma with marrow involvement. 107
Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens. 106
Seventeen years of experience with ATRA-based therapy for acute promyelocytic leukaemia: long-term follow-up of patients treated at S. Martino Hospital, Genoa 105
Next Generation Sequencing and Microrna Assay in a Cohort of Patients Affected By Myelodysplastic Syndromes. an Analysis of Clinical and Genotypic Features 105
Vdelta1 T lymhocites from B-CLL patients recognize ULPB3 expressed on leukemic B cells and up-regulated by trans-retinoic acid 103
GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly. 101
Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation 98
Detection of minimal residual disease in B-lymphoproliferative disorders: a three step SSCP-PCR method. 96
Clonal hematopoiesis impacts frailty in newly diagnosed multiple myeloma patients: a retrospective multicenter analysis 95
Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment? 94
GM-IVA, a short induction course for de novo acute myeloid leukemia, suitable for the elderly. 91
Leucemia mieloide acuta Profilo genetico 91
Monitoring molecular response by BCR-ABL, JH and WT-1 in Ph+ all treated with imatinib containing regimen: preliminary report of two cases. 85
Totale 15.518
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.198
article - articoli 49.905
book - libri 0
conference - conferenze 434
curatela - curatele 0
other - altro 526
patent - brevetti 0
selected - selezionate 0
volume - volumi 333
Totale 102.396
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.206 34 77 87 140 48 85 74 249 67 111 54 180
2022/20231.456 133 122 34 167 246 246 4 102 210 26 146 20
2023/2024908 48 81 23 110 74 208 68 112 30 20 42 92
2024/20252.360 64 163 70 158 234 231 267 434 79 98 285 277
2025/20264.288 534 165 323 347 511 342 660 154 305 384 292 271
2026/2027236 236 0 0 0 0 0 0 0 0 0 0 0
Totale 16.127